RecruitingPhase 1NCT06233942

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Sponsor

BeOne Medicines

Enrollment

308 participants

Start Date

Apr 12, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BG-C9074, a drug called Bevacizumab, and others for people with advanced solid tumor. The study is currently recruiting participants at 38 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBG-C9074

administered by intravenous infusion

DRUGTislelizumab

administered by intravenous infusion

DRUGBevacizumab

administered by intravenous infusion

Locations(37)

Usc Norris Comprehensive Cancer Center (Nccc)

Los Angeles, California, United States

University of Colorado Cancer Center

Aurora, Colorado, United States

Florida Cancer Specialist Research Institute Lake Nona

Orlando, Florida, United States

Sidney Kimmel Comprehensive Cancer At Johns Hopkins

Baltimore, Maryland, United States

James Cancer Hospital and Solove Research Institute

Columbus, Ohio, United States

Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, Australia

Macquarie University

North Ryde, New South Wales, Australia

Cancer Care Wollongong

Wollongong, New South Wales, Australia

Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Monash Health

Clayton, Victoria, Australia

Cabrini Hospital Malvern

Malvern, Victoria, Australia

Peter Maccallum Cancer Centre

Melbourne, Victoria, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

Hospital Sirio Libanes Brasilia

Brasília, Brazil

Liga Norte Riograndene Contra O Cancer

Natal, Brazil

Hospital Sao Lucas Da Pucrs

Porto Alegre, Brazil

Instituto Nacional de Cancer Hospital Do Cancer Ii

Rio de Janerio, Brazil

Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

São José do Rio Preto, Brazil

Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira

São Paulo, Brazil

Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria

São Paulo, Brazil

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Fujian Cancer Hospital

Fuzhou, Fujian, China

Sun Yat Sen University Cancer Center

Guangzhou, Guangdong, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

The Second Hospital of Dalian Medical University

Dalian, Liaoning, China

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

Liaoning Cancer Hospital and Institute

Shenyang, Liaoning, China

Qilu Hospital of Shandong University

Jinan, Shandong, China

Affiliated Hospital of Jining Medical University

Jining, Shandong, China

Weifang Peoples Hospital

Weifang, Shandong, China

Obstetrics and Gynecology Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

Cancer Institute Hospital of Jfcr

Kotoku, Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06233942

Related Trials

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

NCT075125833 locations

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

NCT048906138 locations

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT0722226727 locations

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

NCT065771941 location

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

NCT0722634921 locations